



Issue 40: Friday 29 January 2021

Welcome to our weekly CRN Eastern COVID-19 Research Round-up. Please do let us know if you have suggestions for improving it further by emailing us at covid19.eastern@nihr.ac.uk.

Novavax vaccine proves to be 89.3% effective

As you are undoubtedly aware, the Novavax vaccine trial has this week published results indicating its 89.3% effectiveness in preventing COVID-19. This is extremely good news, and is thanks to the enormous effort of NHS staff across the country to deliver the trial, including our own colleagues at East Suffolk and North Essex, Norfolk and Norwich University Hospitals and North West Anglia NHS Foundation Trusts, and at Wansford Surgery in Peterborough.

We are incredibly grateful to everyone who has been involved in achieving this result, including staff, volunteers and supporters, and look forward with hope for this to be approved as the fourth vaccine for deployment to protect the UK population, and

hopefully beyond. Thank you to everyone who has played a part in this, and all trials to try to help us bring an end to this pandemic.

CCP-UK and VIVALDI moved to Level 1a prioritisation

Both the CCP-UK and the VIVALDI trials have been added to the list of Level 1a priority studies, also including RECOVERY, REMAP-CAP, PRINCIPLE and SIREN. Please scroll down for the full breakdown of priority levels.

Updated vaccine registry images for social media

The CRN Coordinating Centre has now provided updated social media graphics, along with an updated leaflet and poster (all [downloadable from the dedicated webpage](#) or directly access [Twitter assets here](#) and [Instagram assets here](#)) to help promote ongoing vaccine trials across the country. The CC has offered to provide printed supplies of leaflets/posters so if you would like some, please email esther.reeve@nih.ac.uk with your requirements.

Find help on our Hub Home

Take a look at our dedicated [Urgent Public Health Research area](#) on the CRN Eastern Hub Home for links to official guidance and NIHR webpages, and our CRN Eastern Prioritised Studies Dashboard.

CRN Eastern COVID-19 study status

Here is the list of all UPH studies currently in set-up, delivery or recently closed in the Eastern region, listed in alphabetical order.

Key

SD = Studies with significant developments / looking for new sites

OTR = Studies opening/open to recruitment with no significant developments

C = Studies closing soon/closed

EOI = Expression of Interest

UPH = Urgent public health

ADAPT Sepsis (OTR)

In set-up.

This study is open for EOI's. Please contact covid19.eastern@nih.ac.uk for more information.

BASIL + (OTR)

In set-up.

CCP-UK (SD)

LEVEL 1A PRIORITY STUDY

Open and recruiting.

It has been agreed that the ISARIC-CCP-UK study should be prioritised at Level 1a with immediate effect. The CO-CIN case report form has been minimised to focus on new priorities and aid data collection. A revised form should be circulated shortly.

CCP-Cancer UK (OTR)

Open and recruiting.

C-MORE (OTR)

Open and recruiting.

COD-01-T01-01: Rivaroxaban for high risk people with mild COVID-19 (OTR)

In set-up.

DIAMONDS (OTR)

Open and recruiting.

[ENSEMBLE 2 Janssen Vaccine Study \(OTR\)](#)

Open and recruiting.

[FALCON \(OTR\)](#)

Open and recruiting.

[GenOMICC \(OTR\)](#)

Open and recruiting.

[HICC \(OTR\)](#)

Open and recruiting.

[MERMAIDS \(OTR\)](#)

Open and recruiting.

[Neonatal Complications of Coronavirus Disease \(Covid-19\) \(OTR\)](#)

Open and recruiting.

[NOVAVAX COVID Vaccine Study \(SD\)](#)

Closed.

Results published Friday 29 January show that the vaccine has proven to be 89.3% effective in large-scale UK trials. Thank you to everyone at East Suffolk & North Essex, Norfolk and Norwich University Hospitals, Wansford Surgery and all others who played such a vital part in this effort.

[PAN COVID \(OTR\)](#)

Open and recruiting.

[PHOSP-COVID \(OTR\)](#)

Open and recruiting.

(As published in issue 39) The study team is preparing an interim data report for the end of January and they have asked if sites could please focus on data entry and

recruitment to Tier 1. Please can sites input data into RECAP for their Tier 2 participants. The study team is looking for more Tier 1 sites.

PRINCIPLE (SD)

LEVEL 1A PRIORITY STUDY

Open and recruiting.

Results published so far for the PRINCIPLE study have found that the commonly used antibiotics, Azithromycin and Doxycycline, do not reduce recovery time for patients.

PRONTO (OTR)

In set-up.

RAPTOR (OTR)

In set-up.

RECAP (SD)

Open and recruiting.

This study is still open for expressions of interest. Several of the Eastern practices accepted on to the study have recruited and others have until this week to commence recruitment. Those who have not recruited will be removed from the study.

RECOVERY (SD)

LEVEL 1A PRIORITY STUDY

Open and recruiting.

A regional thank you for your tremendous achievement on recruitment of patients. Substantial amendment 13 has been approved and is due to be implemented on Tuesday 2 February 2021. Related documents can be found on [the RECOVERY trial website](#).

RECOVERY - Respiratory Support (OTR)

Open and recruiting.

REMAP-CAP (OTR)

LEVEL 1A PRIORITY STUDY

Open and recruiting.

SIREN (SD)

LEVEL 1A PRIORITY STUDY

Open and recruiting.

Study now badged 1a and the study team are keen for sites to continue recruiting even though they may have reached their target.

TACTIC-R (SD)

Open and recruiting.

There is a focus on this study to achieve a 'sprint' on recruitment.

UKOSS (OTR)

Open and recruiting.

UK-REACH (OTR)

In set up.

VirusWatch (OTR)

Open and recruiting.

(As published in issue 29) Some blood sampling cohort recruitment data is now available on CPMS and reconciliation of this data with site level figures is ongoing. Most clinics have completed blood taking for round one blood samples and final clinics are taking place for the last remaining patients.

The second round of blood taking expected to take place April - July 2021. The upload of recruitment from the household survey cohort generated from GP practice text messaging has also been added to CPMS this week. CRN Eastern sites have made a significant contribution to this study and our thanks go to them for their hard work and dedication in delivering this valuable research.

VIVALDI (SD)

LEVEL 1A PRIORITY STUDY

NEW: In set up.

Understanding SARS-CoV-2 infection, immunity and its duration in care home staff and residents in the UK. The aim of the study is to find out how many care home staff and residents have been infected with COVID-19, to inform decisions around the best approach to COVID-19 testing in the future. Initial tests will be repeated over time to learn how COVID-19 spreads in care homes and how long the antibody response lasts and whether this helps to prevent re-infection with the virus. Information collected, including vaccination data, will also link to national data on hospital admissions and deaths.

This study status now has level 1a priority status. Any organisations with links to Care Homes who would like more information about how to support this study should contact Ruth and Luke via covid19.eastern@nihr.ac.uk The study is designed to run within the care home with care home staff. Support with informed consent and study set up is required for new homes. [A brief video can be shared with care homes.](#)

What's the STORY (OTR)

Open and recruiting.

Current research prioritisation

- **Level 1a:** COVID-19 UPH vaccine and antibody prophylactic studies (as prioritised by the Vaccines Task Force and agreed by Jonathan Van-Tam, deputy CMO), platform therapeutics trials (currently RECOVERY/RECOVERY +; PRINCIPLE; REMAP-CAP, CCP-UK, VIVALDI and SIREN).
- **Level 1b:** Other COVID-19 UPH studies.
- **Level 2:** Studies where the research protocol includes an urgent treatment or intervention without which patients could come to harm. These might be

studies that provide access to potentially life preserving or life-extending treatment not otherwise available to the patient.

- **Level 3:** All other studies (including COVID-19 studies not in Level 1a or 1b).

For further information in relation to any UPH studies, please contact us at covid19.eastern@nhr.ac.uk or visit our dedicated [CRN Eastern Hub Home UPH research site](#).

The CRN Eastern COVID-19 Research Round-up is currently published on the last working day of each week (subject to rescheduling as required). The previous issue can be found on [the CRN Eastern Hub Home UPHR area](#).

This communication is currently sent to CRN Eastern funded staff and a number of non-funded research delivery staff. Please share this with any staff not funded by CRN Eastern who might find it useful. To subscribe, please email crneastern.comms@nhr.ac.uk.

Contact Us | 01603 287457 | CRNEastern@nhr.ac.uk | <http://local.nhr.ac.uk/eastern>